Company profile: Cero Therapeutics
1.1 - Company Overview
Company description
- Provider of cellular immunotherapy centered on a CER T-cell platform that integrates anti-tumor capabilities of the innate and adaptive immune systems into a single T cell, aimed at treating hematologic malignancies and solid tumors.
Products and services
- CER T-cell platform: Engineers single T cells that integrate innate and adaptive anti-tumor capabilities to treat hematologic malignancies and solid tumors, custom-engineered
- CER T-cell platform for hematologic malignancies: Builds single T cells combining innate and adaptive anti-tumor mechanisms to target hematologic malignancies with integrated activity, cell-based
- CER T-cell platform for solid tumors: Produces single T cells unifying innate and adaptive anti-tumor functions to address solid tumors using a combined mechanism, platform-scale
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cero Therapeutics
Miroculus
HQ: United States
Website
- Description: Provider of hands-off sample-to-answer solutions for molecular testing, delivering assay flexibility and automation via an affordable digital microfluidics platform that enables seamless workflow integration from novel molecular protocols to data analytics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Miroculus company profile →
ArQule
HQ: United States
Website
- Description: Provider of clinical-stage biotechnology research and development of cancer therapeutics, employing its ArQule Kinase Inhibitor Platform (AKIP) to design and develop drugs, including ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ArQule company profile →
Cleveland Diagnostics
HQ: United States
Website
- Description: Provider of efficacious, affordable cancer diagnostic tests, including IsoPSA, a blood test designed to improve the accuracy of prostate cancer detection and reduce unnecessary biopsies by distinguishing cancer-related PSA proteins, and the Solvent Interaction Analysis Platform, which measures structural differences in proteins to identify cancer biomarkers and facilitate development of blood tests for cancer diagnostics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cleveland Diagnostics company profile →
Mainz Biomed
HQ: Germany
Website
- Description: Provider of molecular genetic diagnostic solutions for early cancer detection, including ColoAlert, a non-invasive at-home PCR-based colorectal cancer screening test; eAArly DETECT, a multimodal test combining FIT, mRNA biomarkers and AI to differentiate CRC, advanced and non-advanced adenomas; PancAlert, an early-stage pancreatic cancer screening test in development; and ReconAAsense, an FDA PMA pivotal study for next-gen colorectal screening approval.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mainz Biomed company profile →
Loxo Oncology
HQ: United States
Website
- Description: Provider of targeted cancer therapies for genetically defined patient populations, focused on developing biopharmaceutical treatments and rapidly advancing them into the clinic to achieve outsized clinical effects.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Loxo Oncology company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cero Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cero Therapeutics
2.2 - Growth funds investing in similar companies to Cero Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cero Therapeutics
4.2 - Public trading comparable groups for Cero Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →